

Virtual Human Twin (VHT) Models for Cancer Research

Horizon Europe

CODICE	AMBITO
HORIZON-MISS-2026-02-CANCER-01	Internazionale
LOCALITÀ	STATO
Europa	Aperto
PROGRAMMA	CURATO DA
Horizon Europe	Maria Macedo
GENERATO IL	
28 aprile 2026	

Descrizione

Objectives

This incentive aims to advance cancer research by supporting the development of innovative multiscale Virtual Human Twin (VHT) models. The primary objective is to expand the understanding of cancer onset and progression, particularly for cancers with limited treatment options, unclear biological mechanisms, refractory cancers, rare cancers, early-onset cancers, and types with low five-year survival rates. The call targets collaboration across disciplines, including researchers, healthcare professionals, innovators, and patients, fostering interdisciplinary work between medical doctors, patient representatives, health IT experts, AI experts, solution providers, research institutes, EU research infrastructures, and SMEs. Results must be aligned with the EU Cancer Mission objectives and provide open access to VHT platforms and solutions for researchers, healthcare professionals, and citizens.

Project Types

Projects funded under this call will focus on development, validation, and accessibility of dynamic, multiscale VHTs for cancer. Required activities include integrating AI tools to process multimodal and multi-omics patient data, application of FAIR data principles, visualisation technologies (e.g., AR/VR), updating VHTs with longitudinal patient datasets, and ensuring clinical uptake. Eligible expenses include data collection and harmonisation, development and validation of models, open science data sharing, networking and collaboration activities, stakeholder engagement, and costs related to participation in project clusters and joint activities. Proposals involving clinical studies must provide specific annexes according to template guidance.

Funding

The total allocated budget for this call is €35,000,000, with the European Commission expecting to fund approximately 4 projects. The expected EU contribution per project ranges from €8,000,000 to €9,000,000. Funding is provided in the form of grants under Horizon Research and Innovation Actions (RIA), with a maximum funding rate of 100% of

eligible costs for most beneficiaries, as per Horizon Europe rules. There is no explicit minimum project value stated, but the indicative EU contribution range serves as a de facto cap and guidance for project scale.

Key Aspects

The model grant agreement defines project implementation rules, including open science provisions, data management requirements, and intellectual property guidelines prioritizing open access. The single-stage application process closes on 15 September 2026 at 17:00 Brussels time. Funded projects are expected to join the "Understanding" project cluster of the Cancer Mission, participate in joint activities, and contribute to the UNCAN.eu and Advanced VHT platforms. Detailed eligibility requirements and evaluation thresholds (minimum score of 4 for each criterion and 12 in total) apply. Performance will be measured by the accessibility and clinical impact of new VHT models, their adherence to FAIR principles, progress towards Cancer Mission goals, and stakeholder engagement.

Date e Scadenze

DATA DI PUBBLICAZIONE

Non definita

DATA DI APERTURA

10 febbraio 2026

Fasi di Candidatura

- Deadline: 15 settembre 2026 alle ore 15:00 (140 giorni rimanenti)

Dettagli Finanziari

TIPO DI SUPPORTO

Contributo a Fondo Perduto

TASSO MASSIMO DI FINANZIAMENTO

100%

BUDGET

35M€

VALORE DI PROGETTO AMMISSIBILE

Up to 9M€

Criteri e Documenti

Spese Ammissibili

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Condizioni di Accesso

- Legal entities from EU Member States and Associated Countries
- Consortium must include partners from at least three different EU Member States or Associated Countries
- Compliance with general and specific admissibility and eligibility criteria

Criteri di Selezione

- Excellence (scientific and technical merit)
- Impact (contribution to policy and partnership KPIs)

- Quality and efficiency of implementation

Informazioni Obbligatorie

- Application form (Part A and Part B)
- Budget

Indicatori di Risultato

- Number of advanced VHTs developed and validated
- Accessibility of VHT platforms for stakeholders
- Contribution to improved understanding and treatment of cancer
- Integration of AI and FAIR data principles
- Open access to data/models via UNCAN.eu and Advanced VHT platforms

Dettagli Programma UE

ID BANDO

HORIZON-MISS-2026-02

MODALITÀ DI PRESENTAZIONE

Single-stage

PROGETTI PREVISTI

4

CLUSTER

Cancer Mission

CONTRIBUTO UE

€8,000,000.00 to €9,000,000.00

REGOLA DEL TASSO DI FINANZIAMENTO

100% funding for most entities according to Horizon Europe RIA rules; see Horizon Europe General Annexes for exceptions and specific beneficiary types.

Idoneità

Settori Idonei

- Salute e Life Sciences
- ICT e Software

Dimensioni Aziendali

- Micro
- PMI
- Small Mid-Cap
- Mid-Cap
- Grande
- Enti privati non profit
- Enti pubblici

Modalità di Candidatura

- Consorzio / Co-promozione

Tipi di Azione

- Research and development of virtual human twin models
- Clinical validation studies

- Data integration and FAIR data management
 - Open science and digital asset sharing
 - Stakeholder engagement and networking
-

Link Ufficiali

Regolamento Ufficiale:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2026-02-CANCER-01?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&isExactMatch=true&status=31094501,31094502&programmePart=43108557&frameworkProgramme=43108390&deadlineDate=1780182000000,1798675200000>

Pagina Grantavia: <https://grantavia.com/it/incentives/virtual-human-twin-vht-models-for-cancer-research>

Prenota un incontro: <https://calendly.com/ines-carreira-fi-group/reuniao>